Clinical Study of 68Ga Labeled HER2 Affibody Analogues
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the dosimetric properties of the positron emission
tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily
evaluate its diagnosis value in patients with breast or gastric tumors.